Teva Under Pressure As NICE Calls For More Reslizumab Analyses

UK HTA body NICE has called for clarifications and updated analyses in draft guidance on Teva’s MAb biologic Cinqaero, a decision that may give heart to potential competitors in the race to dominate the eosinophilic asthma market.

The market for biologics to treat severe eosinophilic asthma may just have got more competitive, with the UK’s National Institute for Health and Care Excellence (NICE) asking for clarifications and updated cost-effectiveness analyses in its draft guidance for Teva Pharmaceutical Industries Ltd.’s intravenous administered humanized interleukin-5 antagonist MAb Cinqaero (reslizumab).

Cinqaero was launched in the UK this summer for use as add-on therapy in adult patients with severe eosinophilic asthma,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip